Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of an Autologous Stem Cell Product in Patients With a (Sub)Acute Spinal Cord Injury (SCI2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03935724
Recruitment Status : Not yet recruiting
First Posted : May 2, 2019
Last Update Posted : October 15, 2019
Sponsor:
Information provided by (Responsible Party):
Neuroplast

Brief Summary:
This is a multicenter, randomized, double-blind, placebo-controlled and delayed-start phase II/III clinical study.

Condition or disease Intervention/treatment Phase
Spinal Cord Injuries Acute Spinal Cord Injury Paraplegia, Spinal Paraplegia; Traumatic Biological: Neuro-Cells Phase 2 Phase 3

Detailed Description:

Phase II of the study focuses on establishing the safety and efficacy of the fist-in-human administration of Neuro-Cells. In phase III efficacy and safety will be further investigated. Enrollment in phase III of the study will automatically start once all patients have been enrolled and treated in phase II. The recruitment period is estimated at respectively 6 months for both the Phase II and Phase III.

Phase II starts with the enrollment of 16 evaluable patients, randomly divided in two groups of 8 evaluable patients each. After an interim intervention analysis, the phase II study expands into a phase III study, requiring the recruitment of 54 additional evaluable patients. Patients recruited for the phase III part will be randomly divided in two groups of 27 evaluable patients each. Details on the planned analyses can be found in section 8 'Statistical Analysis'.

Both the phase II and phase III part of the trial have a similar setup which includes a screening period (1 - 2 days), a randomization, a treatment period of 1 or 2 days and a total follow-up period of 1 year.

All patients undergo a BM harvesting at the start of their participation in the study and will undergo three LPs, performed to administer Neuro-Cells or placebo and/or to collect CSF for research purposes. Neuro-Cells and placebo are both administered as a single dose by an 'unblinded physician'. This physician is different from the 'blinded Investigators and study nurses' responsible for patient selection and follow-up. This study set-up allows to maintain a double-blind status of the patients and the Investigators responsible for the patients' evaluation throughout the first six months of both studies. This is because, approximately six months after the time of inclusion, the patients assigned to the placebo group will undergo a second BM harvesting and will also receive Neuro-Cells. All patients are followed up until approximately one year after the time of inclusion. All patients will have been treated with Neuro-Cells and will have completed follow-up for at least 6 months post-treatment. Patient recruitment, randomization and blinding, and the primary and secondary objectives are identical in the phase II and the phase III part of the study. The study is completed when the last patient finishes his/her last visit, approximately one year after the time of inclusion.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients are randomized into two groups. First groups receives Neuro-cells, second group receives placebo. After six months second group also receives Neuro-cells. This happens in phase 2 and is repeated in phase 3. Therefore there are 4 groups.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: All parties are masked (except for the care provider administering placebo of Neuro-cells). Unmasking will occur after six months when the placebo group receives Neuro-cells.
Primary Purpose: Treatment
Official Title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayedstart Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : January 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1A Intervention group 8 patients
Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident). N=8
Biological: Neuro-Cells
Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.

Placebo Comparator: 1B Placebo group 8 patients
Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=8
Biological: Neuro-Cells
Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.

Experimental: 2A Intervention group 27 patients
Neuro-Cells treatment at day 1-2 (= 6-8 weeks after TSCI incident) N=27
Biological: Neuro-Cells
Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.

Placebo Comparator: 2B Placebo group 27 patients
Placebo treatment at day 1-2 (= 6-8 weeks after TSCI incident) Neuro-Cells treatment at day 181-182 (= 32-34 weeks after TSCI incident) N=27
Biological: Neuro-Cells
Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.




Primary Outcome Measures :
  1. Physical changes after intrathecal intervention with Neuro-Cells [ Time Frame: 9 months ]
    At approx. 3 months after intrathecal intervention with Neuro-Cells (day 90 for the patients treated 6-8 weeks after the TSCI incident and day 270 for the patients treated at 32-34 weeks after the TSCI incident) a physical examination (checklist) will be done

  2. Increase of motor scores after intrathecal invervention with Neuro-Cells [ Time Frame: 6 months ]
    Increase in the ISNCSCI motor scores with additional 5 points from baseline (visit 2) at 6 months after the intrathecal intervention (day 180) in patients treated with Neuro-Cells


Secondary Outcome Measures :
  1. Increase of motor scores after late administration of Neuro-Cells [ Time Frame: 12 months ]
    Increase in the ISNCSCI motor scores with additional 5 points from baseline (visit 5) at 6 months after the intrathecal intervention (day 360) in patients treated with Neuro-Cells 32 to 34 weeks after the TSCI incident as compared to placebo treated patients

  2. Change in autonomic and sensoric neurological dysfunctionafter intrathecal invervention with Neuro-Cells [ Time Frame: 12 months ]

    The American Spinal Injury Association (ASIA) Impairment Scale involves both a Motor and Sensory examination for each side of the body (left/right).

    The Sensory examination involves 'light touch' and 'pinprick' for each dermatome (28) on both sides of the body (total 56). A score of 0, 1 or 2 can be given to each dermatome resulting in a total max. of 112 points.

    The Motor level is determined by examining the muscle function within each of the 10 myotomes on each side of the body (20 myotomes in total). A score ranging from 1 to 5 can be given resulting in a maximum score of 100.

    The higher the value, the better the outcome.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age range: 18 - 65 years
  • Complete (AIS grade A) or incomplete (AIS grade B or C) TSCI (ISNCSCI-assessed) at time of randomization
  • Randomization can be done within 6-8 weeks after the TSCI incident
  • Level of injury between C6 to T12
  • Voluntary signed informed consent by patients and Investigator before any trial-related procedures are performed

Exclusion Criteria:

  • SCI AIS grade D or E at the start of enrolment
  • Level of SCI above C6 or below T12
  • Positive HIV, hepatitis B or C serology
  • Positive Lues test
  • Total Nuclear Cell (TNC) count < 1x109 TNC
  • Cancer, brain injury, disturbed consciousness, signs/symptoms of neurodegenerative disorder (e.g. stroke, amyotrophic lateral sclerosis, multiple sclerosis etc), diabetes mellitus type 1, renal or cardiac insufficiency based on anamnesis history and at the investigator's discretion
  • Any concomitant treatment or medication that interferes with the conduct of the trial, such as immune-suppressive medication or other medication (especially methotrexate, cyclosporine, and corticosteroids have to be avoided) known to interact with the anti- inflammatory and immune-modulative actions of stem cells (non-steroid anti- inflammatory drugs (NSAIDs) are allowed)
  • Abuse of alcohol (daily consumption of more than 2 units of alcohol containing drinks) or illicit drugs (e.g. heroin, cocaine, XTC)
  • Individuals that belong to vulnerable population groups
  • Females with childbearing potential without using adequate birth control methods, and/or being pregnant or in the lactation period
  • Participation in any clinical trial (with exemption of descriptive studies with questionnaires and no active intervention) within the previous 30 days before enrolment, or simultaneous participation in such trial
  • Patients with extreme comorbidity before or after the TSCI are excluded at discretion of the PI
  • Patients who are unable to comply with the requirements of this clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03935724


Contacts
Layout table for location contacts
Contact: Kimberly de Hoo, MSc +3143 388 5617 k.dehoo@neuroplast.com
Contact: Hans de Munter, MD +3143 388 5617 h.demunter@neuroplast.com

Locations
Layout table for location information
Denmark
Rigshospitalet Not yet recruiting
Copenhagen, Denmark, 2100
Spain
Hospital Nacional de Parapléjicos Not yet recruiting
Toledo, Spain, 45004
Sponsors and Collaborators
Neuroplast
Investigators
Layout table for investigator information
Principal Investigator: Jörg Mey Hospital Nacional de Parapléjicos de Toledo
Principal Investigator: Fin Biering-Soerensen, MD Righospitalet

Additional Information:
Layout table for additonal information
Responsible Party: Neuroplast
ClinicalTrials.gov Identifier: NCT03935724     History of Changes
Other Study ID Numbers: A2017SCI03
First Posted: May 2, 2019    Key Record Dates
Last Update Posted: October 15, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Paraplegia
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Paralysis
Neurologic Manifestations
Signs and Symptoms